Atacicept frequent MRI study in RMS
What it found
No result yet.
What was tested
Treatment tested
- Atacicept
Tumor necrosis factor ligand superfamily member 13 inhibitor|Tumor necrosis factor ligand superfamily member 13B inhibitor
What it measured
Main measures
El criterio de valoración principal es el número medio de lesiones potenciadas con gadolinio (Gd) en T1 por sujeto por prueba desde la semana 12 a la 36, ambas incluidas.
MRI lesions
Who could take part
Relapsing MS
Inclusion: Todos los sujetos deben cumplir todos los criterios siguientes antes de la visita basal/DE1 (primer día de administración de la dosis): Exclusion: Para ser elegible para su inclusión en este estudio los sujetos no deben cumplir ninguno de los criterios siguientes:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
El objetivo principal del estudio es evaluar la eficacia de tres dosis de atacicept para reducir la inflamación del SNC en sujetos con EMR evaluada por RM frecuentes.
Loading reviews and guidelines…
Related trials
- Addition of Belimumab to B-cell Depletion in Relapsing-re…
Phase 2 · Stopped early
Stopped early
- A Study of Participants With Relapsing-Remitting Multiple…
Phase 2 · Completed
Results posted, no main test reported
- ATAMS ext
Phase 2 · Stopped early
Stopped early
- Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Hu…
Phase 2 · Stopped early
- Atacicept 28063 (RMS) extension study
Phase 2 · Completed
No result found
- ATAMS
Phase 2 · Stopped early
Stopped early
History
Started
Jan 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error